Express your opinion about this website:
Traffic report about pomalyst.com - here you can find answers to questions like these:
Our system has never spotted pomalyst.com in Alexa ratings.
This fact suggests that domain has very low traffic.
The most recent time we have spotted pomalyst.com on Quantcast list was on February 6, 2014 (3,734 days ago) and then the rank was 452,515. And this is a bit better position than average position for pomalyst.com in Quantcast.
Website is hosted on IP 50.16.161.63.
The host name of this IP address is ec2-50-16-161-63.compute-1.amazonaws.com.
There are 3 websites hosted on exact the same IP and 117 websites that are hosted on similar IP address.
Our database records shows that this website can be similar to: mdslifebeyondlimits.org, istodax.com, and maybe even more.
We've checked pomalyst.com recently and it was online. The load time was 0.3664 seconds faster than average. The size of document was 35,876 bytes longer than usually. The website contained 53 links more than the average.
It seems that pomalyst.com is optimised for mobile devices.
We did not encounter any safety threats while testing this website.
We did not find any data about pomalyst.com being listed in the blacklists.
It seems that pomalyst.com was never dropped before.
Click here to see the list of dropped domains
Our system found out that there could be 291 domains with the same beginning as pomalyst.com
Our system found out that there could be 44 mistakes made in the typing process.
And here you'll find analysis of HTML code:
| PROPERTY | VALUE |
|---|---|
| Keywords: | POMALYST® (pomalidomide) official website, for USA audiences, indications, dosing, safety, efficacy, administration, prescribing information, multiple myeloma, Important Safety Information, HCP, Healthcare Professionals |
| WEB address: | http://pomalyst.com/ |
| Summary: | POMALYST is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression. Please see the full Indication and Important Safety Information for POMALYST. Indication POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Important Safety Information WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting POMALYST treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping POMALYST treatment. POMALYST is only available through a restricted distribution program called POMALYST REMS®. Venous and Arterial Thromboembolism Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient’s underlying risk factors. CONTRAINDICATIONS Pregnancy: POMALYST can cause fetal harm and is contraindicated in females who are pregnant. If POMALYST is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus. WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity & Females of Reproductive Potential: See Boxed WARNINGS – Males: Pomalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 4 weeks after discontinuing POMALYST, even if they have undergone a successful vasectomy. Males must not donate sperm. – Blood Donation: Patients must not donate blood during treatment with POMALYST and for 1 month following discontinuation of POMALYST therapy because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST. POMALYST REMS® Program: See Boxed WARNINGS – Prescribers and pharmacies must be certified with the POMALYST REMS program by enrolling and complying with the REMS requirements; pharmacies must only dispense to patients who are authorized to receive POMALYST. Patients must sign a Patient-Physician Agreement Form and comply with REMS requirements; female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements and males must comply with contraception requirements. – Further information about the POMALYST REMS program is available at www.CelgeneRiskManagement.com or by telephone at 1-888-423-5436. Venous and Arterial Thromboembolism: See Boxed WARNINGS. Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors. Hematologic Toxicity: Neutropenia (46%) was the most frequently reported Grade 3/4 adverse reaction in patients taking POMALYST in clinical trials, followed by anemia and thrombocytopenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification. Hepatotoxicity: Hepatic failure, including fatal cases, has occurred in patients treated with POMALYST. Elevated levels of alanine aminotransferase and bilirubin have also been observed in patients treated with POMALYST. Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered. Hypersensitivity Reactions: Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reactions, and do not resume therapy. Dizziness and Confusional State: In patients taking POMALYST in clinical trials, 14% experienced dizziness (1% Grade 3 or 4) and 7% a confusional state (3% Grade 3 or 4). Instruct patients to avoid situations where dizziness or confusional state may be a problem and not to take other medications that may cause dizziness or confusional state without adequate medical advice. Neuropathy: In patients taking POMALYST in clinical trials, 18% experienced neuropathy (2% Grade 3 in one trial) and 12% peripheral neuropathy. Second Primary Malignancies: Cases of acute myelogenous leukemia have been reported in patients receiving POMALYST as an investigational therapy outside of multiple myeloma. Tumor Lysis Syndrome (TLS): TLS may occur in patients treated with POMALYST. Patients at risk are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken. ADVERSE REACTIONS Nearly all patients treated with POMALYST + low-dose dex experienced at least one adverse reaction (99%). The most common adverse reactions included neutropenia (51.3%), fatigue and asthenia (46.7%), upper respiratory tract infection (31%), thrombocytopenia (29.7%), pyrexia (26.7%), dyspnea (25.3%), diarrhea (22%), constipation (21.7%), back pain (19.7%), cough (20%), pneumonia (19.3%), bone pain (18%), edema peripheral (17.3%), peripheral neuropathy (17.3%), muscle spasms (15.3%), and nausea (15%). Grade 3 or 4 adverse reactions included neutropenia (48.3%), thrombocytopenia (22%), and pneumonia (15.7%). DRUG INTERACTIONS Avoid concomitant use of POMALYST with strong inhibitors of CYP1A2. Consider alternative treatments. If a strong CYP1A2 inhibitor must be used, reduce POMALYST dose by 50%. USE IN SPECIFIC POPULATIONS Pregnancy: See Boxed WARNINGS. If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. There is a POMALYST pregnancy exposure registry that monitors pregnancy outcomes in females exposed to POMALYST during pregnancy as well as female partners of male patients who are exposed to POMALYST. This registry is also used to understand the root cause for the pregnancy. Report any suspected fetal exposure to POMALYST to the FDA via the MedWatch program at 1-800-FDA-1088 and also to Celgene Corporation at 1-888-423-5436. Lactation: There is no information regarding the presence of pomalidomide in human milk, the effects of POMALYST on the breastfed infant, or the effects of POMALYST on milk production. Pomalidomide was excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed infants from POMALYST, advise a nursing woman to discontinue breastfeeding during treatment with POMALYST. Pediatric Use: Safety and effectiveness have not been established in pediatric patients. Geriatric Use: No dosage adjustment is required for POMALYST based on age. Patients >65 years of age were more likely than patients ≤65 years of age to experience pneumonia. Renal Impairment: Reduce POMALYST dose by 25% in patients with severe renal impairment requiring dialysis. Take dose of POMALYST following hemodialysis on hemodialysis days. Hepatic Impairment: Reduce POMALYST dose by 25% in patients with mild to moderate hepatic impairment and 50% in patients with severe hepatic impairment. Smoking Tobacco: Advise patients that smoking may reduce the efficacy of POMALYST. Cigarette smoking reduces the AUC of pomalidomide by 32% by CYP1A2 induction. Please see full Prescribing Information, including Boxed WARNINGS. |
<title> | POMALYST for Multiple Myeloma Survival | POMALYST (pomalidomide) |
| Hosting information: | Click here for more hosting information |
| Size of HTML code: | +35,876 bytes compared to average |
| Total number of links: | +53 links compared to average |
| Load time: | -0.36640565 seconds compared to average |
| META TAG PROPERTY | VALUE |
| language | en |
| twitter:description | Check out Phase 3 survival data in patients with relapsed/refractory multiple myeloma |
| og:type | article |
| og:site_name | Pomalyst |
| robots | noodp |
| twitter:card | summary |
| distribution | global |
| twitter:title | POMALYST for Multiple Myeloma Survival | POMALYST (pomalidomide) |
| viewport | width=device-width, initial-scale=1, user-scalable=no |
| og:url | http://www.pomalyst.com/ |
| google-site-verification | ERHcsjdBiHV01ngf9ZujCbW-MkvmGjhXVceYH6v7amI |
| og:locale | en_US |
No data about Alexa yet.
This table shows websites that use 50.16.161.63 (ec2-50-16-161-63.compute-1.amazonaws.com) for hosting:
| List of websites | IP address and hostname |
|---|---|
| 50.16.161.63 ec2-50-16-161-63.compute-1.amazonaws.com |
Note: The matching part of IP address is marked with this style.
| Website: | pomalyst.com |
|---|---|
| Most recent position: | 452,515 reached on February 6, 2014 (3,734 days ago) |
| Times found in quant list: | 156 |
| Average position: | 204,755 |
| All time highest position: | 79,750 reached on January 7, 2014 (3,764 days ago) |
| All time lowest position: | 454,125 reached on January 30, 2014 (3,741 days ago) |
There are 291 alternatives to pomalyst.com
We believe that these mistakes can be made in the typing process of "pomalyst.com":
No data about pomalyst.com being in dropped domains database...